Huabo Biopharm Co.

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
IL-17AMonoclonal antibody
Psoriasis
Phase 3
PD-L1 / VEGFMultispecific antibody
Non-Small Cell Lung CancerEndometrial Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Est. primary completion 2027-01-15 · NCT07376629 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

June 2026Filing acceptedHB0017NMPA accepted the marketing application for HB0017 (anti-IL-17A) in psoriasis
CN, NMPA · Source ↗
November 2025Topline resultHB0017Phase 3 of HB0017 in plaque psoriasis met all primary and key secondary efficacy endpoints

Financial reports

No financial reports recorded.